Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features

Abstract Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of prostaglandin E2 and release of leukotrienes....

Full description

Bibliographic Details
Main Authors: Tiago Azenha Rama, José Mário Morgado, Ana Henriques, Luis Escribano, Iván Alvarez‐Twose, Laura Sanchez‐Muñoz, André Moreira, José Romão, Alberto Órfão, Almudena Matito
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Clinical and Translational Allergy
Subjects:
anaphylaxis
mast cell‐mediator release‐associated symptoms
mast cells
mastocytosis
non‐steroidal anti‐inflammatory drug hypersensitivity
Online Access:https://doi.org/10.1002/clt2.12132

Internet

https://doi.org/10.1002/clt2.12132

Similar Items